Survey

Help us improve Glivec.com. Please take our short survey.

TAKE SURVEY
Printer-Friendly Version | Email This Page

References

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med. 2006;355:2408-2417.

2. Druker BJ, Guilhot F, O'Brien S, Larson RA, on behalf of the IRIS. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukaemia in chronic phase (CML-CP): the 5-year update from the IRIS study [abstract]. J Clin Oncol. 2006;24:338s. Abstract 6506. Oral presentation.

3. GLIVEC®(imatinib) 100mg and 400mg Tablets. Summary of Product Characteristics. Available online at: www.emea.europa.eu [accessed 28 January 2009]

4. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukaemia. Recommendations from an expert panel on behalf of the European leukaemiaNet. Blood. 2006;108:1809-1820.

5. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumours. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of European Society for Medical Oncology. Ann Oncol. 2005;16:566-578.

6. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukaemia. Science. 1960;132:1497.

7. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243:290-294.

8. Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306:239-242.

9. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukaemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212-214.

10. Lydon NB, Adams B, Poschet JF, Gutzwiller A, Matter A. An E. coli expression system for the rapid purification and characterization of a v-abl tyrosine protein kinase. Oncogene Res. 1990;5:161-173.

11. Geissler JF, Roesel JL, Meyer T, Trinks UP, Traxler P, Lydon NB. Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase. Cancer Res. 1992;52:4492-4498.

12. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493-502.

13. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukaemia. J Clin Invest. 2000;105:3-7.

14. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.

15. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698.

16. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukaemic cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380-394.

17. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.

18. Druker B, Sawyers C, Talpaz M, Resta D, Peng B, Ford J. Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukaemia patients [abstract]. Paper presented at: American Society of Clinical Oncology, May 15-18, 1999; Atlanta, Ga. Abstract 24.

19. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med. 2001;344:1031-1037.

20. Talpaz M, Sawyers C, Kantarjian H, et al. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukaemias, including chronic myelogenous leukaemia in blast crisis [abstract]. Paper presented at: American Society of Clinical Oncology, May 20-23, 2000; New Orleans, La.

21. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.

22. Kantarjian H, Sawyers C, Hochhaus A, et al. Haematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N Engl J Med. 2002;346:645-652.

23. Gambacorti-Passerini C, Talpaz M, Sawyers C, et al. Five year follow-up results of a phase II trial in patients with late chronic phase (L-CP) chronic myeloid leukaemia (CML) treated with imatinib who are refractory/intolerant of interferon-α [abstract]. Blood. 2005;105. Abstract 1089.

24. Kantarjian HM, Sawyers C, Hochhaus A, et al. Six year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) chronic myeloid leukaemia (CML) post interferon-A (IFN) refractoriness/Intolerance [abstract]. Blood. 2006;108:130a. Abstract 428.

25. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable Haematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukaemia: results of a phase 2 study. Blood. 2002;99:1928-1937.

26. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces Haematologic and cytogenetic responses in patients with chronic myelogenous leukaemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.

27. US Food and Drug Administration. Drug approvals for May 2001. Gleevec approval date: May 10, 2001. Available at: www.fda.gov.Accessed March 3, 2006.

28. Fleishman V, Nocon R. Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous leukaemia . Cambridge, Mass: New England Healthcare Institute; 2004.

29. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med. 2003;348:994-1004.

30. Druker B. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study [abstract]. Paper presented at: American Society of Clinical Oncology, May 18-21, 2002; Orlando, Fla. Abstract 1.

31. Larson RA. Imatinib (STI571, Gleevec) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukaemia (CML): results of a randomized phase III study vs interferon-alfa + cytarabine (IFN+AraC). Paper presented at: American Society of Haematology, December 6-10, 2002; Philadelphia, Pa. Abstract 2.

32. Cervantes F. Durability of responses to imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia (CML): 24-month update from the IRIS study [abstract]. Blood. 2003;102:181a. Abstract 633.

33. Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic phase chronic myeloid leukaemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS study [abstract]. Blood. 2004;102:10a. Abstract 21.

34. Simonsson B. Beneficial effects of cytogenetic and molecular response on long-term outcomes in patients with newly diagnosed chronic myeloid leukaemia in chronic phase treated with imatinib: Update from the IRIS study [abstract]. Blood. 2005;106:52a. Abstract 166.

35. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science. 1998;279:577-580.

36. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.

37. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.

38. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumour. N Engl J Med. 2001;344:1052-1056.

39. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med. 2002;347:472-480.

40. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421-1423.

41. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38(suppl 5):S83-S87.

42. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec(R), Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39:2006-2011.

43. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-1134.

44. Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST--Phase III Sarcoma Group Study S0033 [abstract]. Proc Am Soc Clin Oncol. 2004;23:815. Abstract 9005.

45. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41:1751-1757.

46. Blanke CD, Demetri G, von Mehren M, et al. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumour (GIST) patients (pts) treated with imatinib mesylate [abstract]. J Clin Oncol. 2006;24:526s. Abstract 9528.

47. Demetri G, von Mehren M, Joensuu H, et al. Long-term clinical outcomes of imatinib treatment in patients with advanced gastrointestinal stromal tumours. J Clin Oncol. 2006. Submitted.

48. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 2002;1:31-36.

49. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.

50. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.

51. Sawyers CL. Chronic myeloid leukaemia. N Engl J Med. 1999;340:1330-1340.

52. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukaemia. Blood. 2000;96:3343-3356.

53. Fletcher CDM, Berman JJ, Gorstein F, et al. Diagnosis of gastrointestinal stromal tumours: a consensus approach. Hum Pathol. 2002;33:459-465.

54. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41:2868-2872.

55. Miettinen M, Lasota J. Gastrointestinal stromal tumours--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1-12.

56. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumours: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer. 2005;103:821-829.

57. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumours: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889-894.

58. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumours. Science. 2003;299:708-710.

59. Östman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res. 2001;80:1-38.

60. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumours: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484-495.

61. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumours. Gastroenterology. 2003;125:660-667.